This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Nanjing Sanhome Pharmaceutical Co., Ltd.. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Yexin Liao: Innovator in ACC Inhibitor Compounds
Introduction
Yexin Liao is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit acetyl-CoA carboxylase (ACC). His innovative work holds promise for treating various diseases associated with ACC expression.
Latest Patents
Yexin Liao holds a patent for a compound as an ACC inhibitor and its use. The patent discloses a class of compounds that effectively inhibit ACC, which is crucial in the treatment and prevention of fibrotic diseases, metabolic diseases, cancers, and tissue hyperplasia diseases. The compounds, as shown in formula I or their isomers, pharmaceutically acceptable salts, solvates, crystals, or prodrugs, demonstrate good inhibitory activity against ACC. This positions them as potential therapeutic drugs for various health conditions.
Career Highlights
Yexin Liao is currently associated with Nanjing Sanhome Pharmaceutical Co., Ltd. His work at the company focuses on the research and development of innovative pharmaceutical solutions. His expertise in ACC inhibitors has been instrumental in advancing the company's research initiatives.
Collaborations
Yexin collaborates with notable colleagues, including Yong Wang and Liwen Zhao. Their combined efforts contribute to the ongoing research and development of effective pharmaceutical compounds.
Conclusion
Yexin Liao's contributions to the field of pharmaceutical sciences, particularly through his patent on ACC inhibitors, highlight his role as an innovator. His work has the potential to significantly impact the treatment of various diseases, showcasing the importance of innovation in healthcare.